Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In vitro fertilization devices

This article was originally published in The Gray Sheet

Executive Summary

Makers of IVF devices already in commercial distribution will be allowed to continue marketing the products provided that they have submitted a 510(k) for each device marketed in the U.S. within 60 days, FDA says in a letter posted on its website Feb. 19. Additionally, makers of the devices, which were reclassified into either Class II or Class I in October ("The Gray Sheet" Sept. 14, 1998, p. 16), must register their products and list their establishments with the agency. Adherence to the quality system regulation and "other pertinent FDA regulations," such as medical device reporting, labeling and corrections and removals, also is required. Firms in compliance with the stipulations and the reclassification document may continue marketing their devices until FDA determines that the products are substantially equivalent. Devices found not substantially equivalent will require a premarket application approval to be approved before marketing may resume, the agency says

Latest Headlines
See All
UsernamePublicRestriction

Register

MT011363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel